Compositions comprising bacterial strains
The invention provides compositions comprising bacterial strains for treating and preventing cancer.
1. A pharmaceutical composition comprising:
a therapeutically effective amount of a bacteria strain that comprises a 16s rRNA sequence with at least 95% sequence identity to the polynucleotide of SEQ ID NO: 2;
wherein said therapeutically effective amount of said bacteria strain is an amount sufficient for treating or preventing cancer in a subject, wherein the sequence identity is determined by the Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, and a BLOSUM matrix of 62; and
wherein said bacteria strain is lyophilized and/or the pharmaceutical composition further comprises a pharmaceutically acceptable excipient, diluent, or carrier.
2. A pharmaceutical composition comprising:
a therapeutically effective amount of a bacteria strain of the species Enterococcus gallinarum;
wherein said therapeutically effective amount of said bacteria strain is an amount sufficient for treating or preventing cancer in a subject; and
wherein said bacteria strain is lyophilized and/or the pharmaceutical composition further comprises a pharmaceutically acceptable excipient, diluent, or carrier.
3. The pharmaceutical composition of claim 1 , further comprising a lyoprotectant which is a pharmaceutically acceptable excipient, diluent, or carrier.
4. The pharmaceutical composition of claim 1 , comprising a bacteria strain that comprises the 16s rRNA sequence of SEQ ID NO:2.
5. The pharmaceutical composition of claim 1 , comprising a bacteria strain of the species Enterococcus gallinarum.
6. The pharmaceutical composition of claim 1 , said bacteria strain consisting essentially of the species Enterococcus gallinarum.
7. The pharmaceutical composition of claim 1 , further comprising at least one additional bacteria strain.
8. The pharmaceutical composition of claim 1 , wherein at least 50% of the bacteria strain as measured by an amount of colony forming units (CFU), remains viable after about 1 year of storage when the pharmaceutical composition is stored in a closed container at 25° C. at 95% relative humidity.
9. The pharmaceutical composition of claim 1 , wherein the therapeutically effective amount of the bacteria strain comprises from about 1×10 6 to about 1×10 11 CFU/g of said bacteria strain with respect to a total weight of the pharmaceutical composition.
10. The pharmaceutical composition of claim 1 , wherein the composition is a lyophilized composition.
11. The pharmaceutical composition of claim 1 , further comprising a lipopolysaccharide.
12. The pharmaceutical composition of claim 1 , wherein the therapeutically effective amount is an amount effective to increase production of at least one cytokine selected from the group consisting of IL-6, TNF-α, and IL-1β.
13. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated for oral delivery; and wherein the pharmaceutical composition comprises an enteric coating.
14. The pharmaceutical composition of claim 1 , further comprising a prebiotic compound selected from the group consisting of: a fructo-oligosaccharide, a short-chain fructo-oligosaccharide, inulin, an isomalt-oligosaccharide, a transgalacto-oligosaccharide, a pectin, a xylo-oligosaccharide, a chitosan-oligosaccharide, a beta-glucan, an arable gum modified starch, a polydextrose, a D-tagatose, an acacia fiber, carob, an oat, and a citrus fiber.
15. A vaccine comprising the pharmaceutical composition of claim 1 .
16. A food product that comprises: a therapeutically effective amount of a bacteria strain that comprises a polynucleotide sequence with at least 95% sequence identity to the polynucleotide of SEQ ID NO: 2, wherein the sequence identity is determined by the Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, and a BLOSUM matrix of 62; and a nutritious product.
17. The food product of claim 16 , wherein the nutritious product is a milk-food product, or a milk-based product selected from the group consisting of: a cow's milk, a goat's milk, a sheep's milk, skimmed milk, whole milk, milk recombined from powdered milk, yogurt, curdled milk, curd, sour milk, sour whole milk, butter milk, a whey beverage, a fermented milk, a condensed milk, an infant milk, a flavored milk, and an ice cream.